Heartflow has filed for an initial public offering.
The company recorded sales of $125.8 million and a net loss of $96.4 million last year, according to a filing with the Securities and Exchange Commission on Thursday.
It didn't disclose an expected number of shares or price for the offering.
Heartflow's platform uses artificial intelligence to diagnose and manage coronary artery disease. The company plans to use proceeds from the offering to fund sales, marketing, research and product development, including new products, it said.
The company intends to have its units listed on Nasdaq under the ticker HTFL.
At the request of the copyright holder, you need to log in to view this content
LOGIN / SIGN UPDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.